Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Post by Steveminon Apr 15, 2021 3:25pm
204 Views
Post# 33004703

FYI

FYI
I was speaking with an investor friend of mine who happens to also be invested in Inmed (for 4+ years) - and who has a few other friends who've been invested in Inmed for the same period of time (and happen to hold quite few shares) - and he brought up an interesting point. He said that based on the events that have occurred over the last few years, a case could be made to file a "shareholder derivative action" against Inmed (Adams, other board members and executive directors).
 
Basically claiming that Inmed and its directors, did the following:
- Executive, manager or board member breach of fiduciary duty
- Corporate insiders acting in their own best interests instead of the company’s best interests
- Wasting of corporate assets
- Executive compensation improprieties (Adams certainly is compensated way more than other CEO's of comparable market cap)
- Directors/officers making decisions that are contrary to the best interests of the shareholders
 
These are NOT claims of fraud, but rather impropriety which has led to massive destruction of shareholder wealth.
The end goal would be to remove Adams (and certain other directors) and replace them with other much better suited talentwho share the vision as the shareholders. I've always said that I fully support the replacement of Adams and his cronies soI'd be a fan of this for sure. I think most of us are tired of Adams ignoring shareholder calls/emails as well as his massive dilution and blatant shareholder value destruction all while he gets way over compensated to fail at his job.
 
This is just an idea that apparently has been kicked around (I have no idea if they plan to act on it) and I thought it was interesting and wanted to share since this speaks directly to the frustrations most of us are feeling.
<< Previous
Bullboard Posts
Next >>